Enriqueta Felip, MD, PhD
The European Commission has approved brigatinib (Alunbrig) for the treatment of adult patients with ALK
-positive non–small cell lung cancer (NSCLC) who were previously treated with crizotinib (Xalkori), according to Takeda Pharmaceutical Company, the developer of the ALK inhibitor.1
The approval follows a positive opinion granted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in September 2018. The decision was based on findings from the phase II ALTA trial, in which the overall response rate (ORR) was 56% for patients with pretreated ALK
-positive NSCLC treated with the recommended 180-mg dose of brigatinib.2
Additionally, the median overall survival with this dose was 34.1 months.
... to read the full story